New immune drug plus immunotherapy for liver cancer
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial tests whether adding a new drug (RFA) to an immunotherapy medicine (carrizumab) works better than carrizumab alone for hepatocellular carcinoma, a type of liver cancer. It may help people whose tumors cannot be removed or transplanted and who have not started whole-body (systemic) cancer treatment yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged 18 to 75 years
- Confirmed hepatocellular carcinoma (liver cancer) on tissue/cell testing
- BCLC stage B or C, and your performance status is ECOG 0–2
- Liver function is Child-Pugh A or B, and you’re not a candidate for surgery or liver transplant
- You’ve never had systemic (whole-body) cancer therapy, and you have at least one measurable tumor on CT or MRI
- You must not have had certain procedures recently (no ablation, TACE, or radiotherapy within 3 months) and major health issues must be controlled (heart, lungs, bleeding, infections)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new combination therapy for liver cancer that cannot be surgically removed. It uses an immune-boosting drug (atezolizumab), a drug that blocks blood flow to tumors (bevacizumab), and a type of chemotherapy that is delivered directly into the liver artery (HAIC). This combination may help shrink liver tumors and improve outcomes.
This trial tests a treatment to boost the immune system after a procedure called radiofrequency ablation (RFA) that uses heat to destroy liver tumors. It is for people with colorectal cancer that has spread to the liver but not elsewhere, and aims to see if this can improve outcomes.
This trial tests a combination of a personalized immune cell treatment (made from your own cells) and a pneumococcal vaccine along with an “immune checkpoint” drug after high-dose radiation for certain unresectable liver cancers. The goal is to help your immune system better attack the cancer and to see how safe and effective this approach is.
This trial tests a combination of liver-directed radiation therapy, an immunotherapy drug (which helps your immune system fight cancer), and a drug that blocks blood vessel growth to the tumor. It is for people with advanced liver cancer that cannot be treated with surgery.
This trial tests a combination of immunotherapy (camrelizumab), a targeted drug (rivoceranib), and liver-directed chemotherapy (HAIC) to shrink liver tumors enough to make them removable with surgery. It is for people with intermediate or advanced liver cancer that has not spread outside the liver.
This Phase 2 trial studies whether adding a cancer vaccine (to help the immune system recognize your tumor) to two medicines—atezolizumab and bevacizumab—can better control unresectable or advanced liver cancer. It’s for people who haven’t had prior whole-body (systemic) cancer treatment.
Hear when a new Immunosuppression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.